Release Date: July 11, 2025
Expiration Date: July 11, 2026
Activity Overview
This educational activity is an archive of the live presentation held on May 31, 2025.
For more information about this educational activity, the faculty, and disclosures, please click here.
Target Audience
This educational activity is directed toward physicians, nurses, NPs/PAs, and other HCPs involved in the treatment and management of breast cancer.
Learning Objectives
Upon successful completion of this activity, you should be better prepared to:
- Integrate guideline-based biomarker testing recommendations to personalize care for patients with HR+/HER2– metastatic breast cancer (MBC)
- Assess efficacy and safety data for current and emerging next-generation endocrine agents
- Incorporate recent clinical evidence on the use of next-generation endocrine agents to develop personalized treatment plans for patients with HR+/HER2– MBC
- Apply shared decision-making strategies to effectively manage adverse events and enhance treatment adherence in patients receiving next-generation endocrine agents
William J. Gradishar, MD, FASCO, FACP
Betsy Bramsen Professor of Breast Oncology & Professor of Medicine
Chief, Division of Hematology/Oncology
Feinberg School of Medicine at Northwestern University
Chicago, IL
Disclosures: Co-Investigator: Gilead, Menarini Group, Pfizer; Data Monitoring Committee: Lilly, Menarini Group
Laura Huppert, MD
Assistant Professor
UCSF Medical Center
San Francisco, CA
Disclosures: Advisory Board: AstraZeneca, Pfizer; Book Royalties: McGraw-Hill Education; Grant/Research Support: Gilead, Greenwich LifeSciences, Inc, Johnson & Johnson, Pfizer
Yuan Yuan, MD, PhD
Medical Director, Breast Oncology
Cedars-Sinai Medical Center
Los Angeles, CA
Disclosures: Advisor: Astra Zeneca, Genentech, Gilead; Grant/Research Support: Summit; Speaker: Novartis
Faculty, Staff, and Planners’ Disclosures
The staff of Physicians’ Education Resource®, LLC (PER®) have no relevant financial relationships with ineligible companies.
PER mitigated all COI for faculty, staff, and planners prior to the start of this activity.
Off-Label Disclosure and Disclaimer
This activity may or may not discuss investigational, unapproved, or off-label use of drugs. Learners are advised to consult prescribing information for any products discussed. The information provided in this accredited activity is for continuing education purposes only and is not meant to substitute for the independent clinical judgment of a health care professional relative to diagnostic, treatment, or management options for a specific patient’s medical condition. The opinions expressed in the content are solely those of the individual faculty members and do not reflect those of PER or any company that provided commercial support for this activity.